Pulmonary toxicity associated with treatment with amiodarone

Authors

  • Jesús Lancha-Domínguez Servicio de Neumología. Hospital Universitario Juan Ramón Jiménez. Huelva. España
  • María del Mar Ramírez-Sánchez Servicio de Medicina Familiar y Comunitaria. Hospital Universitario Juan Ramón Jiménez. Huelva. España
  • María Inmaculada Páez-Rubio Servicio de Medicina Interna. Hospital Universitario Juan Ramón Jiménez. Huelva. España

DOI:

https://doi.org/10.32818/reccmi.a4n2a6

Keywords:

amiodarone, pulmonary toxicity, pulmonary infiltrates, organized pneumonia.

Abstract

Amiodarone is a widely used antiarrhythmic. Its continued use and the accumulated dose increase the possibility of side effects, mainly thyroid disease, acute toxic hepatitis and pulmonary toxicity. The pulmonary affectation by amiodarone appears in around 5-10% of the patients that use this drug. The organized pneumonia is the most common form of affectation. It can present as interstitial pneumonitis, respiratory distress syndrome (ARDS) or pulmonary or pleural nodules. The delay in diagnosis and withdrawal of the drug plays a fundamental role in its resolution.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Sánchez S, Zamora E, Hoyos N, Naranjo A, Al-Nakeeb Z, Girón RM. Fibrosis pulmonar por amiodarona. Rev Patol Respir. 2006; 9(2): 77-80.

Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J. 2009; 16(2): 43-48. doi: https://doi.org/10.1155/2009/282540.

Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug induced interstitial lung disease: a systematic review. J Clin Med. 2018; 7(10). pii: E356. doi: https://doi.org/10.3390/jcm7100356.

Jackevicius CA, Tom A, Essebag V, Eisenberg MJ, Rahme E, Tu JV, et al. Population level incidence and risk factors for pulmonary toxicity associated with amiodarone. Am J Cardiol. 2011 Sep 1; 108(5): 705-710. doi: https://doi.org/10.1016/j.amjcard.2011.04.024.

Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I). Chest. 1988; 93(5): 1067-1075. doi: https://doi.org/10.1378/chest.93.5.1067.

Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, Manali ED. Amiodarone: review of pulmonary effects and toxicity. Drug Saf. 2010; 33(7): 539-558. doi: https://doi.org/10.2165/11532320-000000000-00000.

Mankikian J, Favelle O, Guillon A, Guilleminault L, Cormier B, Jonville-Béra AP, et al. Initial characteristics and outcome of hospitalized patients with amiodarone pulmonary toxicity. Respir Med. 2014; 108(4): 638-646. doi: https://doi.org/10.1016/j.rmed.2014.01.014.

Camus P, Martin WJ, Rosenow EC. Amiodarone pulmonary toxicity. Clin Chest Med. 2004 Mar; 25(1): 65-75. doi: https://doi.org/10.1016/S0272-5231(03)00144-8.

Colby R, Geyer H. Amiodarone induced pulmonary toxicity. JAAPA. 2017; 30(11): 23-26. doi: https://doi.org/10.1097/01.JAA.0000524713.17719.c8.

Published

2019-08-31

How to Cite

1.
Lancha-Domínguez J, Ramírez-Sánchez M del M, Páez-Rubio MI. Pulmonary toxicity associated with treatment with amiodarone. Rev Esp Casos Clin Med Intern [Internet]. 2019 Aug. 31 [cited 2024 Nov. 23];4(2):57-60. Available from: https://www.reccmi.com/RECCMI/article/view/386